{"Clinical Trial ID": "NCT00630032", "Intervention": ["INTERVENTION 1:", "Docetaxel", "3 cycles of FEC100 (F and C, each at 500 mg/m2, E 100 mg/m2, every 3 weeks) followed by 3 cycles of D (100 mg/m2 every 3 weeks)", "Cyclophosphamide: 500 mg/m2 every 3 weeks Docetaxel: 100 mg/m2 every 3 weeks Epirubicin hydrochloride: 100 mg/m2 every 3 weeks Fluorouracil: 500 mg/m2 every 3 weeks", "INTERVENTION 2:", "Ixabepilone", "3 cycles of FEC100 (F and C, each at 500 mg/m2, E 100 mg/m2, every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m2 every 3 weeks);", "Cyclophosphamide: 500 mg/m2 every 3 weeks Epirubicin hydrochloride: 100 mg/m2 every 3 weeks Fluorouracil: 500 mg/m2 every 3 weeks Ixabepilone: 40 mg/m2 every 3 weeks"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "\u2022 Inclusion criteria:", "Invasive unilateral breast cancer, proven histologically (regardless of the type)", "Initial clinical condition compatible with full initial resection", "No residual macro or microscopic tumours after surgical excision", "(N+) or a negative disease (-) meeting the following criteria:", "Phase II or III of the disease", "- PT > 20 mm (T1-4)", "Patients should meet 1 of the following criteria:", "* Triple-negative tumour* (HER2 negative, estrogen-receptor [ER] negative, and progesterone receptor [PR] negative) OR double-negative (HER2 negative, PR negative, and ER+)", "Node-negative patients: triple-negative tumour* only", "Note: *The negativity of hormone receptors is defined as ER <10% and PR <10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative", "\u2022 Must be able to start chemotherapy no later than day 49 after initial surgery", "- Exclusion criteria:", "Clinically or radiologically detectable metastases (M0)", "\u2022 Bilateral breast cancer or contralateral canalic carcinoma in situ", "Any metastatic alteration, including homolateral involvement of subclavicle nodes, whatever its type", "Any T4a tumour (cutaneous invasion, deep adhesion, inflammatory breast cancer)", "HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive", "Any clinically or radiologically suspect and unexplored damage within the contralateral", "CHARACTERISTICS OF PATIENTS:", "\u2022 Inclusion criteria:", "Women", "Pre- or post-menopausal", "ECOG Performance Status 0-1", "\u2022 Peripheral neuropathy grade 1", "Number of neutrophils 2000/mm3", "Number of platelets 100 000/mm3", "Hemoglobin >9 g/dL", "ASAT and ALT 1.5 times the upper limit of normal (ULN)", "- Alkaline phosphatase 2.5 times ULN", "Total bilirubin 1.0 times ULN", "Serum creatinine level 1.5 times ULN", "LVEF 50% by MUGA scan or echocardiography", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception for up to 8 weeks after completion of study therapy.", "- Exclusion criteria:", "\u2022 Previous cancer (except for basocellular skin epithelioma or peripheral uterine epithelioma) in the previous five years, including invasive contralateral breast cancer", "Patients with another serious and/or uncontrolled medical disease or infection that may compromise their participation in the study", "A clinically significant cardiovascular disease in the past 6 months, including one of the following:", "A unstable angina", "Congestive heart failure", "- Uncontrolled hypertension (i.e., blood pressure > 150/90 mm Hg)", "Myocardial infarction", "- Strokes in the brain", "known severe hypersensitivity reactions to agents containing Cremophor EL", "* Patients with a psychological, family, sociological or geographical condition that may impede compliance with the study protocol and the follow-up schedule", "Patients deprived of their liberty or placed under the authority of a guardian", "THERAPE PRIOR CONCURENT:", "At least 2 weeks after minor surgery (excluding breast biopsy) and adequate recovery", "At least 3 weeks since previous major surgery and properly recovered", "No prior chemotherapy, hormonal treatment or radiotherapy", "More than 72 hours since previous treatment and no concomitant treatment with any of the following potent CYP3A4 inhibitors:", "- Amiodarone", "- Clarithromycin", "Amprenavir", "- Delavirdine", "Voriconazole", "Erythromycin", "- Fluconazole", "Itraconazole", "- Ketoconazole", "Indinavir", "- Nelfinavir", "- Ritonavir", "- Saquinavir", "No simultaneous participation in another therapeutic trial involving an experimental drug"], "Results": ["Performance measures:", "Percentage of participants with disease-free survival (SDF)", "DFS is defined as the interval between the date of randomization and the date of the relapse of breast cancer (local, regional or remote) or the date of breast cancer or death of any cause, whichever occurs first.", "Time limit: 5 years", "Results 1:", "Title of the arm/group : Docetaxel", "Description of the arm/group: 3 cycles of FEC100 (F and C, each at 500 mg/m, E 100 mg/m, every 3 weeks) followed by 3 cycles of D (100 mg/m every 3 weeks)", "Cyclophosphamide: 500 mg/m every 3 weeks Docetaxel: 100 mg/m every 3 weeks Epirubicin hydrochloride: 100 mg/m every 3 weeks Fluorouracil: 500 mg/m every 3 weeks", "Total number of participants analysed: 398", "Type of measurement: Number", "Unit of measure: percentage of participants 78.97 (74.53 to 82.73)", "Results 2:", "Title of the arm/group: Ixabepilone", "Description of the arm/group: 3 cycles of FEC100 (F and C, each at 500 mg/m, E 100 mg/m, every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m every 3 weeks);", "Cyclophosphamide: 500 mg/m every 3 weeks Epirubicin hydrochloride: 100 mg/m every 3 weeks Fluorouracil: 500 mg/m every 3 weeks Ixabepilone: 40 mg/m every 3 weeks", "Total number of participants analysed: 364", "Type of measurement: Number", "Unit of measure: percentage of participants 83.37 (79.06 to 86.87)"], "Adverse Events": ["Undesirable Events 1:", "Total: 207/398 (52.01 per cent)", "Anemia 1/398 (0.25%)", "Aplasia bone marrow 1/398 (0.25%)", "1/398 febrile aplasia (0.25%)", "- Neutropenia febrile 56/398 (14.07 %)", "- Lymphocele 0/398 (0.00 %)", "Neutropenia 141/398 (35.43%)", "Atrial fibrillation 1/398 (0.25%)", "Acute coronary syndrome 0/398 (0.00 %)", "Tachycardia 1/398 (0.25%)", "- Ear disorder 0/398 (0.00 %)", "Adverse Events 2:", "Total: 158/364 (43.41%)", "Anemia 2/364 (0.55%)", "1/364 (0.27%)", "- Febrile aplasia 4/364 (1.10 per cent)", "Febrile neutropenia 27/364 (7.42%)", "- Lymphocele 1/364 (0.27%)", "- Neutropenia 95/364 (26.10 per cent)", "Atrial fibrillation 0/364 (0.00 %)", "- Acute coronary syndrome not ST 1/364 (0.27%)", "Tachycardia 1/364 (0.27%)", "1/364 (0.27%)"]}